Reaction
Folate Deficiency reporting signals
As of the last recalculation, Folate Deficiency appears in 1,131 FAERS reports alongside 33 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 42.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ado-Trastuzumab Emtansine | 19 | 42.2 | 42.3 |
| Lopinavir And Ritonavir | 23 | 31.9 | 31.9 |
| Mupirocin | 20 | 27.8 | 27.8 |
| Mupirocin Calcium | 20 | 27.2 | 27.3 |
| Gentamicin | 19 | 27.2 | 27.2 |
| Febuxostat Tablets 40 Mg | 14 | 25.6 | 25.7 |
| Febuxostat Tablets 80 Mg | 14 | 25.6 | 25.7 |
| Pertuzumab | 33 | 23.0 | 23.0 |
| Gentamicin Sulfate | 19 | 22.5 | 22.5 |
| Piperacillin Sodium,Tazobactam Sodium | 29 | 20.6 | 20.6 |
| Nebivolol | 16 | 18.7 | 18.8 |
| Febuxostat | 16 | 17.8 | 17.8 |
| Torsemide | 30 | 17.1 | 17.1 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 9 | 15.1 | 15.1 |
| Piperacillin And Tazobactam | 10 | 14.5 | 14.5 |
| Nevirapine | 7 | 14.4 | 14.4 |
| Filgrastim | 26 | 13.0 | 13.0 |
| Meropenem | 22 | 12.8 | 12.9 |
| Granisetron Hydrochloride | 7 | 12.4 | 12.4 |
| Granisetron | 7 | 12.4 | 12.4 |
| Efavirenz | 7 | 11.6 | 11.6 |
| Dolutegravir Sodium | 5 | 10.2 | 10.2 |
| Docetaxel Anhydrous | 34 | 9.5 | 9.5 |
| Docetaxel | 34 | 9.5 | 9.5 |
| Trastuzumab | 33 | 9.1 | 9.1 |
| Atazanavir | 7 | 9.0 | 9.0 |
| Rotigotine | 6 | 7.7 | 7.7 |
| Olaparib | 8 | 7.1 | 7.1 |
| Cenobamate | 3 | 6.6 | 6.6 |
| Ocrelizumab | 21 | 6.3 | 6.3 |
| Brivaracetam | 3 | 6.2 | 6.2 |
| Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide | 3 | 5.5 | 5.5 |
| Vigabatrin | 3 | 3.8 | 3.8 |